Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
Ranjan PathakGilberto De Lima LopesHan YuMadan Raj AryalWenyan JiKatherine Stemmer FrumentoChristopher J D WallisZachary KlaassenHenry S ParkSarah B GoldbergPublished in: Cancer (2020)
Although chemoimmunotherapy appears to improve the ORR and PFS in patients with PD-L1-high tumors when compared with single-agent ICI, it does not appear to confer an OS benefit over single-agent or dual-agent ICI for patients with advanced NSCLC regardless of PD-L1 status. Prospective trials are needed to validate these findings.